Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4998546 | 0.90 | LIPE (0.49) | LIPEPRMT5WDR77SMN1; SMN2MEN1 | |
| SCHEMBL5002260 | 0.86 | LIPE (0.49) | LIPESMN1; SMN2MEN1KMT2ATAAR1 | |
| SCHEMBL5004388 | 0.84 | LIPE (0.46) | LIPEPRMT5WDR77SMN1; SMN2MEN1 | |
| SCHEMBL4989293 | 0.83 | LIPE (0.48) | LIPESMN1; SMN2MEN1KMT2ATAAR1 | |
| SCHEMBL5004377 | 0.82 | LIPE (0.46) | LIPESMN1; SMN2MEN1KMT2ATAAR1 | |
| SCHEMBL4998710 | 0.81 | LIPE (0.45) | LIPESMN1; SMN2MEN1KMT2ATAAR1 | |
| SCHEMBL4992807 | 0.79 | LIPE (0.46) | LIPESMN1; SMN2MEN1KMT2ATAAR1 | |
| SCHEMBL5002014 | 0.79 | LIPE (0.46) | LIPESMN1; SMN2MEN1KMT2ATAAR1 | |
| SCHEMBL5002208 | 0.79 | LIPE (0.46) | LIPESMN1; SMN2MEN1KMT2ATAAR1 | |
| SCHEMBL5505424 | 0.76 | LIPE (0.41) | LIPESMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227792-A1 | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters | NOVO NORDISK A/S (DK) | 2008-09-18 | — | — | US | claimed |
| US-20080227792-A1 | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters | NOVO NORDISK A/S (DK) | 2008-09-18 | — | — | US | disclosed |
| US-20080227792-A1 | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters | NOVO NORDISK A/S (DK) | 2008-09-18 | — | — | US | disclosed |
| US-20080227792-A1 | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters | NOVO NORDISK A/S (DK) | 2008-09-18 | — | — | US | disclosed |
| EP-1853585-A1 | 3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID 5-AMINOPYRIDIN-2-YL ESTERS | Novo Nordisk A/S (DK) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006087309-A1 | 3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID 5-AMINOPYRIDIN-2-YL ESTERS | NOVO NORDISK A/S (DK) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227792-A1 | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters | LIPE, LIPC, PNLIP | LIPE 1/4885PRMT5 1561/4885WDR77 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.